Hippocrates Research
Hippocrates Research is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
Asciminib as single agent or in combination with nilotinib in the 1st-line treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a GIMEMA-GELMC phase II study. CML1624
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Sponsor Reata Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Enrollment was concentrated in the United States (131/172 participants), with 21 participants enrolled in the EEA: Austria 14 and Italy 7.
- The Part 2 primary mFARS analysis set excluded participants with pes cavus and included Week 48 data from 34 omaveloxolone-treated and 41 placebo-treated participants.
These findings describe the trial, not the service provider’s performance or responsibility.
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE HYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).
Sponsor Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Sponsor Y-mAbs Therapeutics A/S
- Start (EU)
- Latest update
- Estimated end
A Pivotal, Randomized, Placebo-Controlled, Double-Blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)
Sponsor Rheacell GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study
Sponsor Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-2)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
Sponsor University Of Antwerp
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, multiCentre, dOuble-blind, double-duMmy, parallel-group clinical study on efficacy and safety of iBuprofen/N-acetylcysteine fixed dose cOmbination vs. its individual components (ibuprofen and N- acetylcysteine monotherapies) in patients with symptomatic uncomplicated upper respiratory tract infections with wet cough COMBO
Sponsor E Pharma Trento S.p.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hippocrates Research?
The 2026-10-09 snapshot links Hippocrates Research to 12 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Data management, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hippocrates Research?
The most frequently recorded therapeutic areas are Dermatology, Haematological Malignancies, Genetic and Congenital Disorders, Infectious Disease. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hippocrates Research conducted?
The linked trials record locations in 14 countries, including Italy, Spain, Poland, France, Austria. These are trial locations, not confirmed office locations or countries where Hippocrates Research delivered services.
What can this page tell me about Hippocrates Research's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hippocrates Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hippocrates Research S.r.l.